Mayo Clinic | Strategic Alliance Partners

Check out this October recap of OncLive’s coverage of the top news and expert insights in breast cancer.

The top 5 OncLive TV videos of the week cover insights in CRC at ESMO 2026, dMMR rectal cancer, chronic neutropenia, pediatric LGG, and MSS CRC.

Gastrointestinal oncologists weigh HER2 testing practices, the order of HER2-directed therapies, and emerging agents for metastatic colorectal cancer.

Frank A. Sinicrope, MD, previews 2 colorectal cancer studies to watch at the 2026 ESMO Congress, including adjuvant intensification and AZUR-1.

Patients with pancreatic cancer experience measurable changes in body composition years before diagnosis that differ from those seen in similar individuals without cancer.

The 510(k) clearance covers an MRI-derived AI risk score for stage I to IIIA disease; the high-risk category carried an HR of 2.81 for recurrence.

Researchers in a Mayo Clinic-led study have shown how to detect a broad range of DNA mutations in noncancerous human tissues and across the genome.

Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, and Sikander Ailawadhi, MD, discuss potential avenues for at-home administration in myeloma.

Matthew P. Goetz, MD, discusses gedatolisib, treatment sequencing, and co-targeting resistance pathways in HR-positive, HER2-negative advanced breast cancer.

The FDA has approved atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery.

Matthew P. Goetz, MD, discusses oral SERD trial findings, PI3K-pathway therapies, and emerging CDK-targeted treatments in HR-positive advanced breast cancer.

Matthew P. Goetz, MD, explores menopausal status, recurrence risk, and adjuvant CDK4/6 inhibitor selection in HR-positive breast cancer.

Matthew P. Goetz, MD, explores first-line treatment selection, emerging targeted therapies, and unmet sequencing needs in metastatic breast cancer.

Frank A. Sinicrope, MD, discusses the FDA approval of the ATOMIC trial regimen for patients with stage III dMMR colon cancer.

Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.

Mayo Clinic researchers led a multicenter study that found dividing radiation into several treatments, known as fractionated stereotactic radiosurgery, reduced the risk of cancer returning after surgery

Experts highlight the integration of subcutaneous therapies into the multiple myeloma treatment paradigm.

MAPK drugs restore TSHR in aggressive thyroid tumors, helping CAR-T cell therapy see and control solid tumors again.

Mayo Clinic researchers reported data for minibeam radiotherapy for treatment-resistant cancers in or near the skin.

Mayo Clinic researchers identified a potential new approach to treating glioblastoma to improve the effectiveness of existing chemotherapy.

Three new articles from The Lancet Hematology published today examine how clinicians and researchers can better identify, track and measure the effects of blood cancer treatments on patients during treatment and over the long term.

Sagar Lonial, MD, FACP, FASCO, and Sikander Ailawadhi, MD, discuss the investigation of cemsidomide in relapsed/refractory multiple myeloma.

Rafael Fonseca, MD, breaks down the integration of CAR T-cell therapy as a treatment for early relapsed multiple myeloma.

Rafael Fonseca, MD, discusses why CAR T-cell therapy could be considered at first relapse in multiple myeloma.

Rafael Fonseca, MD, discusses how FISH, NGS, and minimal residual disease testing guide risk stratification and treatment in multiple myeloma.

In an OncLive Peer Exchange, experts discussed the evolving treatment landscape in CLL, spanning frontline selection to emerging next-generation agents.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.

Colorectal cancer is not the only gastrointestinal cancer that doctors are diagnosing in patients below the age of 50.

Continuing maintenance therapy with lenalidomide beyond 2 years after initial treatment did not improve overall survival in standard-risk myeloma.

A Mayo Clinic study found that a new immunotherapy helped patients with aggressive bladder cancer keep their bladder instead of having it removed.